MedTrace Logo

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

NCT05371028 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2025-04-06

No results posted yet for this study

Summary

The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in Canada.

This study is about collecting existing data only; participants receive teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. No new information will be collected during this study.

The study will be conducted using data from the Takeda OnePath Patient Support Program (PSP) or Takeda Global Pharmacovigilance.

Conditions

  • Short Bowel Syndrome (SBS)

Interventions

OTHER

Non-interventional Study

This is non-interventional study.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-23
Primary Completion
2025-02-19
Completion
2025-02-19

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05371028 on ClinicalTrials.gov